

ACELRX PHARMACEUTICALS INC  
Form 8-K  
October 02, 2015  
**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 2, 2015**

**ACELRX PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**                    **001-35068**                    **41-2193603**  
(State of incorporation) (Commission File No.) (IRS Employer Identification No.)

**351 Galveston Drive**

**Redwood City, CA 94063**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 216-3500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 7.01. Regulation FD Disclosure.**

AcelRx Pharmaceuticals, Inc. (the “Company” or “AcelRx”) hosted an Analyst & Investor Day on Friday, October 2 in New York from 12:00pm – 2:00pm ET. Members of the management team will discuss the AcelRx late-stage product candidates, Zalviso™ and ARX-04. A comprehensive update was also provided on ARX-04, including recently reported and updated clinical results, anticipated market size and regulatory plans. An update was also provided on Zalviso, which was recently approved for sale in the European Union. The presentation handout, together with a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation handout, are furnished as Exhibit 99.1 to this Current Report and are incorporated herein by reference. The presentation handout is also available in the “Investor Relations” section of AcelRx Pharmaceuticals, Inc.’s website, located at [www.ace.rx.com](http://www.ace.rx.com).

The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

**Description**

**Number**

99.1	Slide presentation entitled, “AcelRx Pharmaceuticals, Inc. New York Analyst Day Presentation October 2, 2015”
------	---

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  
October ACELRX PHARMACEUTICALS, INC.  
2, 2015

By:                               /s/ Jane  
                                      Wright-Mitchell  
                                      Jane  
                                      Wright-Mitchell  
                                      Chief Financial  
                                      Officer

---

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Slide presentation entitled, "AcelRx Pharmaceuticals, Inc. New York Analyst Day Presentation October 2, 2015"